Literature DB >> 20033156

Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease.

Kjell Någren1, Christer Halldin, Juha O Rinne.   

Abstract

Alzheimer's disease (AD) is a common degenerative neurological disease that is an increasing medical, economical, and social problem. There is evidence that a long "asymptomatic" phase of the disease exists where functional changes in the brain are present, but structural imaging for instance with magnetic resonance imaging remains normal. Positron emission tomography (PET) is one of the tools by which it is possible to explore changes in cerebral blood flow and metabolism and the functioning of different neurotransmitter systems. More recently, investigation of protein aggregations such as amyloid deposits or neurofibrillary tangles containing tau-protein has become possible. The purpose of this paper is to review the current knowledge on various (18)F- and (11)C-labelled PET tracers that could be used to study the pathophysiology of AD, to be used in the early or differential diagnosis or to be used in development of treatment and in monitoring of treatment effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20033156     DOI: 10.1007/s00259-009-1301-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  139 in total

1.  Evaluation of reference regions for (R)-[(11)C]PK11195 studies in Alzheimer's disease and mild cognitive impairment.

Authors:  Marc A Kropholler; Ronald Boellaard; Bart N M van Berckel; Alie Schuitemaker; Reina W Kloet; Mark J Lubberink; Cees Jonker; Philip Scheltens; Adriaan A Lammertsma
Journal:  J Cereb Blood Flow Metab       Date:  2007-04-04       Impact factor: 6.200

2.  Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment.

Authors:  A Nordberg; H Lundqvist; P Hartvig; J Andersson; M Johansson; E Hellstrŏm-Lindahi; B Långström
Journal:  Dement Geriatr Cogn Disord       Date:  1997 Mar-Apr       Impact factor: 2.959

3.  Radiochemical synthesis and tissue distribution of p-[18F]DMPPF, a new 5-HT1A ligand for PET, in rats.

Authors:  Caroline Defraiteur; Christian Lemaire; André Luxen; Alain Plenevaux
Journal:  Nucl Med Biol       Date:  2006-06-12       Impact factor: 2.408

Review 4.  Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development.

Authors:  Mats Bergström; Anders Grahnén; Bengt Långström
Journal:  Eur J Clin Pharmacol       Date:  2003-08-22       Impact factor: 2.953

5.  Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease.

Authors:  N Kemppainen; M Laine; M P Laakso; V Kaasinen; K Någren; T Vahlberg; T Kurki; J O Rinne
Journal:  Eur J Neurosci       Date:  2003-07       Impact factor: 3.386

6.  Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment.

Authors:  L Truchot; S N Costes; L Zimmer; B Laurent; D Le Bars; C Thomas-Antérion; B Croisile; B Mercier; M Hermier; A Vighetto; P Krolak-Salmon
Journal:  Neurology       Date:  2007-09-04       Impact factor: 9.910

7.  Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106.

Authors:  Fumihiko Yasuno; Miho Ota; Jun Kosaka; Hiroshi Ito; Makoto Higuchi; Talant K Doronbekov; Shoko Nozaki; Yota Fujimura; Michihiko Koeda; Takashi Asada; Tetsuya Suhara
Journal:  Biol Psychiatry       Date:  2008-06-02       Impact factor: 13.382

8.  Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease.

Authors:  Ahmadul Kadir; Niels Andreasen; Ove Almkvist; Anders Wall; Anton Forsberg; Henry Engler; Göran Hagman; Marie Lärksäter; Bengt Winblad; Henrik Zetterberg; Kaj Blennow; Bengt Långström; Agneta Nordberg
Journal:  Ann Neurol       Date:  2008-05       Impact factor: 10.422

9.  A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [11C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([11C]AFM).

Authors:  Yiyun Huang; Dah-Ren Hwang; Sung-A Bae; Yasuhiko Sudo; Ningning Guo; Zhihong Zhu; Raj Narendran; Marc Laruelle
Journal:  Nucl Med Biol       Date:  2004-07       Impact factor: 2.408

10.  Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls.

Authors:  N M Scheinin; S Aalto; J Koikkalainen; J Lötjönen; M Karrasch; N Kemppainen; M Viitanen; K Någren; S Helin; M Scheinin; J O Rinne
Journal:  Neurology       Date:  2009-09-02       Impact factor: 9.910

View more
  3 in total

1.  In vitro and ex vivo characterization of (-)-TZ659 as a ligand for imaging the vesicular acetylcholine transporter.

Authors:  Hui Liu; Hongjun Jin; Junfeng Li; Xiang Zhang; Kota Kaneshige; Stanley M Parsons; Joel S Perlmutter; Zhude Tu
Journal:  Eur J Pharmacol       Date:  2015-02-09       Impact factor: 4.432

Review 2.  Brain imaging in the study of Alzheimer's disease.

Authors:  Eric M Reiman; William J Jagust
Journal:  Neuroimage       Date:  2011-12-07       Impact factor: 6.556

3.  Behavioral Changes and Hippocampus Glucose Metabolism in APP/PS1 Transgenic Mice via Electro-acupuncture at Governor Vessel Acupoints.

Authors:  Jin Cao; Yinshan Tang; Yujie Li; Kai Gao; Xudong Shi; Zhigang Li
Journal:  Front Aging Neurosci       Date:  2017-01-24       Impact factor: 5.750

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.